secwatch.observer — SEC 8-K summary
======================================

Issuer:     Propanc Biopharma, Inc. (PPCB)
CIK:        0001517681
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001641172-25-015642
Event type: debt
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital
--------------------------------------------------------------------------------

- Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.
- Note sold at $22,500 (10% OID); prepayment options with premiums from 110% to 125% within first 180 days.
- Received $13,188 AUD loan from board member at 12% interest, maturing June 30, 2025.
- Proceeds from both financings will be used for general working capital purposes.
- Note is subject to 4.99% beneficial ownership limitation; conversion price adjusts on default.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/0001641172-25-015642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer